Loading stock data…
bioAffinity Technologies, Inc. (BIAF)
$0.80-0.03 (-3.18%)
After Hours$0.81+0.01 (+1.05%)· Last close Jun 29
bioAffinity Technologies, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
bioAffinity Technologies, Inc. in the Healthcare sector is trading at $0.80 with a market capitalization of $8M. The stock is currently near its 52-week low of $0.69, remaining 62.6% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 15 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 15) — potential for technical mean-reversion
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.35M↓ | $1.54M↑ | $1.45M↑ | $1.27M↓ | $1.85M |
| Gross Profit | $422,891↓ | $638,687↑ | $503,855↑ | $252,881↓ | $485,737 |
| Operating Income | -$3.62M↓ | -$3.19M↓ | -$2.29M↑ | -$2.52M↑ | -$2.63M |
| Net Income | -$3.63M↓ | -$3.14M↑ | -$5.05M↓ | -$4.06M↓ | -$2.66M |
Peer Comparison
JNJUNHPFE
Fundamentals
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates thro...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$7.66M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-1.19
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-433.71%
Volume
Today's trading volume
172,599
Recent News
BIAF Stock Slips Post Q1 Earnings Despite Strength in CyPath Lung
bioAffinity posts softer first-quarter 2026 results after exiting lower-margin pathology services, though CyPath Lung adoption and clinical-trial progress gain traction.
bioAffinity Stock Surges 113.8% in 3 Months: What's Driving the Rally?
BIAF is sharpening its focus on CyPath Lung, streamlining unprofitable services and pushing validation studies as it expands its lung-disease pipeline.
BC-Most Active Stocks
Nu Holdings Ltd. 74,509,403 14.92
BIAF vs. GH: Which Cancer Detection Stock Is the Better Buy Now?
bioAffinity leans on its CyPath Lung sputum test for early lung cancer detection, while Guardant Health expands liquid biopsy and screening. Which strategy is ahead? Let's see.
BIAF Stock Dips After Q3 Earnings Reflect Lower Sales and Wider Loss
bioAffinity's third-quarter 2025 performance shows lower sales and a wider loss as it pivots to focus on CyPath Lung and expands VA system adoption.